TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Researchers examine ‘concerning’ out-of-hospital 30-day mortality rate for TAVR patients

Researchers examined data from more than 98,000 patients who underwent transfemoral TAVR from January 2015 to March 2018. 

Thumbnail

TAVR in the time of COVID-19: Providers quickly adapted, delivering ‘excellent’ outcomes

Researchers compared patient outcomes from 2019 with data from the pandemic’s first four months, sharing their findings in the American Journal of Cardiology.  

Thumbnail

No reason to quit: TAVR patients can continue anticoagulation therapy throughout procedure

Patients are typically told to put anticoagulation therapy on hold two to four days before they undergo TAVR. This study’s authors aimed to see if this was truly necessary.  

Thumbnail

CKD patients on dialysis face worse TAVR outcomes, including a higher risk of in-hospital mortality

The authors examined data from more than 42,000 patients who received care from 2012 to 2017. 

Thumbnail

In-hospital stroke rates higher after TAVR than MitraClip procedures

Post-discharge stroke rates, however, were similar between the two procedures.

Thumbnail

An eye on imaging: How to limit radiation exposure during TAVR procedures

Specialists at a high-volume facility in Germany were able to successfully limit radiation dose—and patient outcomes did not suffer. 

Thumbnail

Skip the clopidogrel? TAVR patients benefit from antiplatelet therapy that includes aspirin only

The risk of major bleeding or life-threatening bleeding events was higher when clopidogrel was included in the patient's treatment strategy. 

Boston Scientific to retire Lotus Edge TAVR program after voluntary recall

The company will now focus its attention on the marketing and development of other solutions.

Displaying 361 - 368 of 401
Design by Adaptive Theme